Format

Send to

Choose Destination
Ann Palliat Med. 2018 Oct;7(4):463-477. doi: 10.21037/apm.2018.06.04. Epub 2018 Jun 28.

Cannabis in palliative care: current challenges and practical recommendations.

Author information

1
Department of Family Medicine, McGill University, Montreal, Canada. claudecyrmd@gmail.com.
2
Department of Oncology, McGill University, Montreal, Canada; Clinique Santé Cannabis, Montreal, Canada.
3
Department of Rehabilitation Medicine, Department of Geography, University of Washington, Seattle, WA, USA.
4
College of Nursing, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
5
Department of Family Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada.
6
Pharmacy Department, CHUM (Centre Hospitalier de l'Université de Montréal), Montreal, Canada.
7
Clinique Santé Cannabis, Montreal, Canada.

Abstract

Pain and symptom control challenges are common in palliative care, and the search for other therapeutic strategies is ongoing. Unfortunately, patients and their caregivers are receiving little information or support from healthcare providers regarding the increasingly popular cannabinoid-based medicines (CBM). Clinicians, meanwhile, feel understandably perplexed by the discrepancy between the available evidence and the rapid interest in which patients and their families have demonstrated for CBM. There is an urgent need to address the many challenges that are delaying the appropriate integration of CBM into clinical practice, notwithstanding the obvious need for a solid general knowledge of pharmacology, mechanism of action and available clinical evidence supporting its use. The authors will address these challenges and provide practical recommendations regarding patient assessment for the use of CBM. The authors will also make suggestions regarding patient expectations in order to define clear objectives, review the necessary precautions prior to initiating treatment, aid in selecting the appropriate strain and route of administration as well as establishing proper titration and monitoring protocols. The authors will also discuss the lesser known but potentially therapeutic psychoactive effects of cannabis. As this class of therapeutic agents are likely to play a major role in palliative medicine in the near future, clinicians would benefit from familiarizing themselves with CBM and we can expect that patients and their caregivers will appreciate receiving support in their search for safe and effective therapeutic alternatives.

KEYWORDS:

Medical cannabis; cannabinoids; palliative care; quality of life; review; symptom control

PMID:
30180728
DOI:
10.21037/apm.2018.06.04
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for AME Publishing Company
Loading ...
Support Center